Abstract
The Watson-Crick base pairing rule provides the underlying principle for the antisense (AS) approach to inhibiting gene expression. Transforming growth factor α (TGFα) was the first growth factor to be associated with tumorigenesis, thus making the TGFα (mRNA) a potential target for AS therapy and offering the potential for monitoring of the progression of malignancy by non-invasive imaging with radiolabelled AS phosphodiester. Probe labelling and biodistribution were studied in the present report. A 23-mer oligonucleotide sequence was synthesized and grafted in 5′ with a tyramine group which was further radioiodinated. The radiolabelled AS was injected intratumorally in mammary tumour-bearing BALB/c mice (3 weeks after inoculation of 7·106 NS2T2A mammary cells). Biodistribution was monitored by sequential scintigraphy and organ radioactivity after autopsy. The 5′ tyramine group allowed specific and stable radiolabelling of the AS with125I. The125I AS oligonucleotide was rapidly cleared from the tumour by intestine and kidneys. Four hours after intratumoral injection, 6.5%±1.5% of the dose was retained in the tumour as non-degraded125I AS. It is concluded that 5′ tyraminylated AS provides information on the biodistribution of AS oligonucleotide following intratumoral injection. These data will contribute to the pharmacology of AS oligonucleotides which can be used for therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Agrawal S, Tang JY An antisense oligonucleotide phosphorothioate as therapeutic agent for AIDS.Antisense Res Dev 1992; 2: 261–266.
Zamenick PC, Stephenson ML. Inhibiting of Roux sarcoma virus replication and cell transformation by specific oligodeoxynucleotide.Proc Natl Acad Sci USA 1978; 75: 280–284.
Watson PH, Pon RT, Shin RPC. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer.Cancer Res 1991; 51: 3996–4000.
Helene C, Saison-Behmoaras E. La stratégie antisens: nouvelles approches thérapeutiques.Med Sci 1994; 10: 253–273.
Pierga JY, Cammilleri S, Benyahia B, Magdelenat H. Applications des oligonucléotides antisens en cancérologie.Bull Cancer Radiother 1994; 81: 1023–1042.
Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents. Is the bullet really magical?Science 1993; 261: 1004–1012.
Dewanjee MK, Ghafouripour AK, Kapadvanjwala, Dewanjee S, Serafini AN, Lopez DM, Sfakianakis GN. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model.J Nucl Med 1994; 35: 1054–1063.
Piwnica-Worms D. Making sense out of anti-sense: challenges of imaging gene translation with radiolabeled oligonucleotides.J Nucl Med 1994; 35: 1064–1066.
Lu X-ML, Fishman AJ, Jyawook SL, Hendricks K, Tompkins RG, Yarmush ML. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake.J Nucl Med 1994; 35: 269–275.
Urbain JLC, Shore SK, Vekemans MC, Cosenza SC, Deriel K, Patel GV, Charkes ND, Malmud LS, Reddy EP. Scintigraphic imaging of oncogenes with antisense probes: does it make sense? Eur J Nucl Med 1995; 22: 499–504.
Cammilleri S, Perdereau B, Brixy F, Pierga JY, Benyahia B, Chypre C, Magdelenat H. Biodistribution d'un oligonucléotide phosphodiester radiomarqué (1251) chez la souris same.Med Nucl 1995; 19: 20–24.
Sizeland AM, Burgess AW. Antisense transforming growth factor α oligonucleotides inhibit autocrine stimulated proliferation of a colon carcinoma cell line. Mol Biol Cell 1992, 3: 1235–1243.
Hunter WM. The preparation of radioiodinated proteins of high activity; their reaction with antibody in vitro. In: Davis A, ed:Handbook of experimental immunology. Philadelphia: Mosby; 1967: 608–642.
Berthon P, Goubin G, Dutrillaux B, Degeorges A, Faille A, Gespach C, Calvo F. Single-step transformation of human breast epithelial cells by SV40 large T oncogene.Int J Cancer 1992; 52: 92–97.
Berthon P, Pancino G, Cremoux P, Roseto A, Gespach C, Calvo F. Characterization of normal breast epithelial cells in primary cultures: differentiation and growth factor receptor studies.In Vitro Cell Dev Biol 1992; 28A: 716–724.
Wickstrom EL, Racon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom EL. Human promyelocytic leukemia HL-60 proliferation and c-myc protein expression are inhibited an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.Proc Natl Acad Sci USA 1988; 85: 1028–1032.
Weintraub H, Izant JG, Harland RM. Antisense RNA as a molecular tool for genetic analysis.Trends Genet 1985; 1: 22–25.
Gewirtz AM, Anfosst G, Venturelli D, Valpreda S, Sims R, Calabretta B. G1/s transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myc.Science 1989; 245: 180–183.
Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers IM. A c-myc antisense oligonucleotide inhibits entry into S phase but not progress from G0 to G1.Nature 1987; 328: 445–449.
Wilks AF, Kurban RR, Dunn AR. Direct demonstration of an autocrine mechanism in EMS-induced, tumorigenic mutants of the growth factor-dependent hemopoietic cell line, FDC-P1.Growth Factors 1989; 2: 31–42.
Becker D, Merer CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor.EMBO J 1989; 8: 3685–3691.
Todaro GJ, De Larco JE. Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells.Nature 1976; 264: 26–31.
Todaro GJ, Fryling C, De Larco JE. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors.Proc Natl Acad Sci USA 1980; 77: 5258–5262.
Marquardt H, Todaro GJ. Human transforming growth factor production by a melanoma cell line, purification and initial characterization.J Biol Chem 1982; 257: 5220–5225.
Massague J. Epidermal growth factor like transforming growth factor.J Biol Chem J 1983; 258: 13606–13613.
Fontanel ML, Bazin H, Roget A, Teoule R. Synthesis and use of 4-hydroxyphenyl derivatized phosphoramidites in the selective radioiodination of oligonucleotide probes.J Labelled Compd Radiopharm 1993; 33: 20–26.
Sauvaigo S, Fouque B, Roger A, Livache T, Bazin H, Teoule R. Fast solid support detection of PCR amplified viral DNA sequences using radioiodinated or hapten labelled primers.Nucleic Acids Res 1990; 11: 3175–3178.
Zamecnik PC, Goodchild J, Tagachi TG, Sarin P. Inhibition of replication and expression of human T-cell lymphotropic virus type II in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.Proc Natl Acad Sci USA 1986; 83: 4143–4146.
Harel-Bellan A, Ferris DK, Conocur M. Specific inhibition ofc-myc protein biosynthesis using an antisense synthetic deoxyoligonucleotide in human T lymphocytes.J Immunol 1988; 140: 2431–2435.
Borries D, Raynal MC, Solomon DH. Down regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells.Cell 1989; 59: 959–968.
Becker D, Meir CB, Heilyn M. Proliferation of human malignant melanomas targeted against basic fibroblast growth factor.EMBO J 1989; 8: 3685–3691.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cammilleri, S., Sangrajrang, S., Perdereau, B. et al. Biodistribution of iodine-125 tyramine transforming growth factor α antisense oligonucleotide in athymic mice with a human mammary tumour xenograft following intratumoral injection. Eur J Nucl Med 23, 448–452 (1996). https://doi.org/10.1007/BF01247375
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01247375